These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24337692)

  • 21. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
    Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
    Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
    Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population.
    Caughey GE; Gabb GM; Ronson S; Ward M; Beukelman T; Hill CL; Limaye V
    JAMA Intern Med; 2018 Sep; 178(9):1224-1229. PubMed ID: 30073275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab therapy in necrotizing autoimmune myopathy associated with anti-SRP antibody: A clinical case review.
    Nóvoa Medina FJ; Gutiérrez Martínez J; González González Y; Romero Díaz B; Machín García S; Rosas Romero A
    Reumatol Clin (Engl Ed); 2018; 14(6):379-381. PubMed ID: 28389200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term rituximab treatment of refractory idiopathic inflammatory myopathy: A report of 3 cases].
    Yi WX; Wei CJ; Wu Y; Bao XH; Xiong H; Chang XZ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 53(6):1191-1195. PubMed ID: 34916704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
    Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
    Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No hepatitis B reactivation in a patient with refractory antisynthetase syndrome successfully treated with rituximab.
    Andres M; Courtney P
    Joint Bone Spine; 2011 Dec; 78(6):653-4. PubMed ID: 21807545
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
    Birgens H; Frederiksen H; Hasselbalch HC; Rasmussen IH; Nielsen OJ; Kjeldsen L; Larsen H; Mourits-Andersen T; Plesner T; Rønnov-Jessen D; Vestergaard H; Klausen TW; Schöllkopf C
    Br J Haematol; 2013 Nov; 163(3):393-9. PubMed ID: 23981017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
    Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
    Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study.
    Leclair V; Galindo-Feria AS; Dastmalchi M; Holmqvist M; Lundberg IE
    Rheumatology (Oxford); 2019 Jul; 58(7):1214-1220. PubMed ID: 30690633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre.
    Manwatkar A; Naresh K; Mathew J; Nair AV; Goel R; Yadav B; Prakash JAJ; Das JK; Sivadasan A
    Rheumatology (Oxford); 2024 May; ():. PubMed ID: 38814804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic Strategies for Idiopathic Inflammatory Myopathies].
    Tomimitsu H
    Brain Nerve; 2023 May; 75(5):511-516. PubMed ID: 37194522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of the inflammatory myopathies: update and practical recommendations.
    Hengstman GJ; van den Hoogen FH; van Engelen BG
    Expert Opin Pharmacother; 2009 May; 10(7):1183-90. PubMed ID: 19405792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy.
    Garcia-Hernandez FJ; Gonzalez-Leon R; Castillo-Palma MJ; Sanchez-Roman J
    Clin Exp Rheumatol; 2011; 29(2):363-4. PubMed ID: 21385551
    [No Abstract]   [Full Text] [Related]  

  • 36. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
    Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
    An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
    Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
    Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre.
    Loarce-Martos J; Lilleker JB; Parker M; McHugh N; Chinoy H
    Rheumatology (Oxford); 2021 Jul; 60(7):3398-3403. PubMed ID: 33367878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
    Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
    Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K; Sallam HT; Hakim AA; Al-Attiyah R
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):973-8. PubMed ID: 22982909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.